Research Analysts’ Weekly Ratings Changes for Nurix Therapeutics (NRIX)

Several brokerages have updated their recommendations and price targets on shares of Nurix Therapeutics (NASDAQ: NRIX) in the last few weeks:

• 6/9/2026 – Nurix Therapeutics had its price target raised by BTIG Research from $30.00 to $32.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Nurix Therapeutics had its price target raised by Truist Financial Corporation from $30.00 to $32.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Nurix Therapeutics was downgraded by Wells Fargo & Company from “overweight” to “hold”. They now have a $25.00 price target on the stock, down from $28.00.
• 6/8/2026 – Nurix Therapeutics had its price target raised by Jefferies Financial Group Inc. from $41.00 to $45.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Nurix Therapeutics had its price target raised by Needham & Company LLC from $26.00 to $34.00. They now have a “buy” rating on the stock.
• 5/18/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $30.00 price target on the stock.
• 4/27/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.
• 4/23/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $26.00 price target on the stock.
• 4/21/2026 – Nurix Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/10/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.

Insider Buying and Selling

In other Nurix Therapeutics news, CFO Houte Hans Van sold 14,055 shares of the stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $16.60, for a total transaction of $233,313.00. Following the transaction, the chief financial officer owned 37,592 shares in the company, valued at $624,027.20. This trade represents a 27.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 3,214 shares of the firm’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $16.65, for a total transaction of $53,513.10. Following the completion of the sale, the insider owned 120,399 shares in the company, valued at approximately $2,004,643.35. The trade was a 2.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 19,657 shares of company stock valued at $326,586 over the last three months. 6.70% of the stock is owned by insiders.

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.